603707.SH
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.06
−0.74%Oct 30, 2026, 09:14 UTC
Jianyou Shares reported first-three-quarter 2026 revenue of 3.006 billion yuan, up 2.74% year over year, and attributable net profit of 273 million yuan, down 36.40%.
Source:Oct 30, 2026, 09:14 UTC
Jianyou Shares reported third-quarter 2026 revenue of 1.08 billion yuan, up 14.13% year over year, and attributable net profit of 85.5969 million yuan, down 40.23%.
Source:Oct 30, 2026, 09:13 UTC
The U.S. Food and Drug Administration approved Jianyou Shares’ salmon calcitonin injection for marketing in the United States.
Source:Oct 28, 2026, 23:50 UTC
Tianxiang Investment Consulting reported that technology and pharmaceutical companies dominated the top 50 stocks newly added to mutual funds’ major holdings by the end of the third quarter of 2026.
Source:Jul 6, 2026, 08:36 UTC
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. received a drug registration certificate from the National Medical Products Administration for its propofol emulsion injection 20ml:200mg, marking the approval for marketing in China.
Source: